How exaptation mediates the effects of customer participation on low-cost innovation: The role of strategic flexibility

With the advent of emerging markets, the need for low-cost innovation to meet the rising demands of people at the base of the pyramid has increased significantly. Although the critical influence of customer participation on new product development has been recognized, there have been few studies on the effects of customer participation on low-cost innovation. This study builds a moderated mediation model and explores the roles of customer participation on low-cost innovation. Based on the exaptation and strategic flexibility theories, the mediating role of exaptation and the moderating role of strategic flexibility are emphasized. A survey of 348 firms revealed that customer participation positively impacted both exaptation and low-cost innovation. In addition, exaptation mediated the correlation between customer participation and low-cost innovation. Resource flexibility negatively moderated the correlation between customer participation and exaptation and negatively moderated the mediating effect of exaptation. Furthermore, coordinate flexibility positively moderated the correlation between customer participation and exaptation and positively moderated the mediating effect of exaptation.

Innovation in crisis: The role of 'exaptive relations' for medical device development in response to COVID-19

The COVID-19 pandemic has resulted in huge disruption to the healthcare sector. In response to this, there have been collaborative efforts between many different public and private organizations to foster medical innovations. The effect of crisis upon innovation, particularly medical innovation, remains a debatable subject. In addition, the role of inter-personal relations is becoming more widely acknowledged as a critical feature of innovation. Drawing upon exaptation literature, the study aims to understand the nature of the micro-relations within medical innovations that are undertaken in response to COVID-19. The findings of this paper contribute to the limited literature that examines the performance of medical innovation in response to crisis. In addition to confirming the importance of exaptive pools, exaptive events, and exaptive forums in fostering serendipitous developments, the study makes a contribution to theory by identifying a further form of serendipitous encounter that is 'exaptive relations'.

Variants of drill as preparations for responding to surprising events

Purpose

This paper aims to contribute to research on management training and development by exploring the impact of extensive training labeled as drill on coping with critical situations. More specifically, it inquires into conditions and supplements for drill to move from mere adaptation to exaptation, relating to the transfer of drilled procedures to serve novel requirements, in events involving different types of surprise.

Design/methodology/approach

The paper adopts an interpretive research approach. Data were collected through semi-structured interviews with members of the Austrian Military on cases of resilient field action in manifold situations of surprise.

Findings

The paper reveals that two different kinds of drill lead to properties that are essential for recovery from shock during critical events: the pure drill and the preaptative drill. Pure drill enables automatized action in situations when time or emotional pressure is too high for reflection or consideration of different options. Preaptative drill, pertaining to drill enhanced with background knowledge, leads to adaption or even exaptation of automatized action through reflection.

Originality/value

The present paper is the first to show the potential impact of drill on the ability to deal with specific kinds of surprise. It suggests that incorporating explanatory background knowledge about why and how rules and learned behaviors that were created into training programs can be of vital importance for dealing with surprise successfully.

Correlations of Resource Bricolage and Exaptation With Low-Cost Breakthrough Innovations: Moderating Effect of Organizational Agility

The mechanism influencing resource bricolage driving low-cost breakthrough innovations remains unclear. By introducing exaptation and organizational agility, this study creates a regulated mediation model, explores effects of resource bricolage on low-cost breakthrough innovations, and analyzes the moderating effect of organizational agility and mediation effect of exaptation. The results revealed that resource bricolage exerted a significant positive impact on low-cost breakthrough innovations, and exaptation played a mediation role between resource bricolage and low-cost breakthrough innovations. In addition, both marketing agility and operational agility positively regulated the correlation between resource bricolage and exaptation. Further research revealed that the mediation effect of exaptation was positively regulated by marketing agility and operational agility, respectively. Overall, this study enriches the discussion of the impact mechanism of breakthrough innovations by resource bricolage and provides valuable enlightenment for enterprises to implement innovation-driven development strategies in the context of economic transformation.

Technological exaptation and crisis management: Evidence from COVID‐19 outbreaks

One of the key issues in the field of technology analysis and innovation management is how new technologies origin and evolve in the presence of environmental threats. We confront this problem focusing on emerging innovative solutions to cope with unexpected and harmful problems posed by crises and needing a rapid, effective response. We specifically analyze the patterns of critical innovations to cope with new coronavirus disease (COVID‐19) that is generating public health and economic issues worldwide. Accordingly, in the context of the theory of technological exaptation, we adopted a narrative approach examining vital innovations that ended up treating COVID‐19 even though they were originated to treat other diseases (more or less distant from the COVID‐19 domain), as the antiviral drug Remdesivir and the antirheumatoid arthritis drug Tocilizumab. Results reveal that technological exaptation, especially if characterized by a longer exaptive distance, is a potential driving force of innovation to cope with COVID‐19 in the short‐term and other similar issues. On this basis, we provide propositions for a more general crisis model of innovation. This study adds a new perspective that may be helpful to explain the evolution of innovation in the presence of crises, considering technological exaptation in a context of environmental threats.

Repurposing without purpose? Early innovation responses to the COVID‐19 crisis: Evidence from clinical trials

The novel coronavirus has created one of the biggest social and economic challenges in recent decades. Since a critical issue in overcoming a large‐scale pandemic involves finding effective treatments for the disease, there is typically urgent pressure on the health‐care sector to develop innovations to combat the pandemic. Recently, scholars have argued that repurposing – that is, reusing an existing innovation in a different context – allows for such rapid innovation responses and can reduce costs, as the groundwork has already been laid. In this paper, we compare these benefits with the considerable disadvantages associated with innovation repurposing, including lowered barriers to entry, which can lead to declining average quality and duplicate work. Using data on 2,456 COVID‐19‐related clinical trials initiated between December 2019 and July 2020, we find that merely one‐third of the trials actually investigated drugs or vaccines, whereas the rest focused on diagnostics and crisis management issues. In the trials concerning drug testing, we find that drug repurposing is a predominant innovation strategy, but many trials tested the same (combination of) drugs. This indicates an inefficient use of resources and reductions in the average variety and novelty of clinical trials. Furthermore, the small percentage of biopharmaceutical firms involved in the search for COVID‐19 treatments raises the question of whether firms may have insufficient incentives to redirect innovation efforts to respond to the pandemic. Our paper contributes to crisis management research, the nascent debate on COVID‐19, and the emerging literature on innovation repurposing.